Geron Corporation (NASDAQ: GERN) saw its stock price soar by 6.82% in pre-market trading on Wednesday following the release of its first-quarter 2025 financial results. The biopharmaceutical company, focused on developing treatments for hematologic malignancies, reported better-than-expected earnings per share (EPS) and operating income, despite missing revenue estimates.

According to the company's report, Geron posted a quarterly EPS of -$0.03, surpassing the analyst consensus estimate of -$0.04 by 25%. This represents a significant improvement from the -$0.09 per share loss reported in the same period last year. The company's operating income came in at -$16.704 million, outperforming the estimated -$23.5 million loss projected by analysts.

While Geron's quarterly sales of $39.60 million fell short of the $48.22 million analyst estimate, it still marked a substantial increase from the $304,000 reported in the same quarter of the previous year. This growth in revenue, coupled with the better-than-expected bottom-line results, appears to have bolstered investor confidence in the company's financial health and operational efficiency, driving the stock's positive movement in early trading.